Can I Take Turmeric / Curcumin With Evenity (Romosozumab)?

What Is Romosozumab and Why Does It Matter?

Romosozumab (Evenity) is a monoclonal antibody that binds and inhibits sclerostin, a protein that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously stimulates osteoblast activity and reduces osteoclast-driven bone resorption, a dual mechanism no other approved osteoporosis drug shares. The FDA approved it in April 2019 for postmenopausal women with severe osteoporosis at high fracture risk [1].

Clinical Efficacy at a Glance

The FRAME trial (N=7,180) showed romosozumab 210 mg monthly reduced new vertebral fractures by 73% versus placebo at 12 months (P<0.001) [2]. The ARCH trial (N=4,093) demonstrated a 48% reduction in new vertebral fractures compared with alendronate over 24 months [3]. These numbers explain why physicians are reluctant to disrupt a 12-month treatment window with avoidable supplement interactions.

The Boxed Warning You Must Know

Evenity carries an FDA boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death [1]. Patients with a history of MI or stroke within the prior year are not candidates for this drug. This warning is not directly related to curcumin, but it is the primary reason your prescriber will want a complete supplement list before each injection.

How Romosozumab Is Metabolized

As a monoclonal antibody, romosozumab is catabolized through normal immunoglobulin degradation pathways, not through cytochrome P450 enzymes [4]. This single fact rules out the most common mechanism of drug-supplement interactions. Curcumin is known to modulate CYP3A4, CYP1A2, and P-glycoprotein [5], but because romosozumab bypasses those pathways entirely, a pharmacokinetic clash is not expected.

How Turmeric and Curcumin Work in the Body

Curcumin is the principal polyphenolic compound in Curcuma longa (turmeric root). It accounts for roughly 2-5% of dried turmeric powder by weight [6]. The supplement market offers curcumin extracts standardized to 95% curcuminoids, doses ranging from 200 mg to 2,000 mg per capsule, far exceeding what a culinary serving provides.

Absorption and Bioavailability

Curcumin has notoriously poor oral bioavailability. Without a lipid carrier or piperine (black pepper extract), peak plasma concentrations after a 2,000 mg oral dose may remain below 50 ng/mL [7]. Formulations using phospholipid complexes, nanoparticles, or piperine can increase absorption 20-fold [7], which matters clinically because higher systemic concentrations raise the theoretical magnitude of any pharmacodynamic effect.

Antiplatelet and Anticoagulant Properties

A 2012 review in Molecular Nutrition and Food Research documented curcumin's inhibition of thromboxane B2 synthesis and collagen-induced platelet aggregation in vitro [8]. A small clinical study (N=30) found that 500 mg/day curcumin for four weeks produced measurable, though modest, reductions in platelet aggregation compared with baseline [9]. These effects are substantially weaker than aspirin or clopidogrel, but they are real at high supplement doses.

Anti-inflammatory Mechanisms

Curcumin inhibits NF-kB signaling, COX-2 expression, and pro-inflammatory cytokines including IL-6 and TNF-alpha [10]. These pathways overlap with normal bone remodeling signaling. Osteoclast differentiation is partly driven by RANKL, which is itself regulated by inflammatory cytokines. Whether curcumin's anti-inflammatory load meaningfully disrupts the bone-remodeling milieu during romosozumab therapy is unknown; no published trial has examined this question directly.

The Specific Interaction: What the Evidence Actually Shows

The honest clinical answer is that direct evidence for a romosozumab-curcumin interaction does not exist in the published literature as of early 2025. No randomized trial, pharmacokinetic study, or large observational cohort has examined this pairing. What clinicians work from is mechanistic inference drawn from each agent studied separately.

Pharmacokinetic Interaction: Low Probability

Because romosozumab is a large-molecule biologic cleared by proteolytic catabolism rather than hepatic CYP enzymes, curcumin's documented CYP3A4 inhibition cannot reduce or increase romosozumab plasma exposure [4]. P-glycoprotein modulation by curcumin is similarly irrelevant to a subcutaneously injected monoclonal antibody. Pharmacokinetic interaction risk is rated as negligible by this mechanistic analysis.

Pharmacodynamic Interaction: Possible at High Doses

The relevant concern is additive pharmacodynamic effects at the injection site and systemically. Romosozumab is administered as two consecutive 105 mg subcutaneous injections (one in each abdomen, thigh, or upper arm) once monthly [1]. Injection-site reactions, including bruising and hematoma, occur in approximately 4.7% of patients in clinical trials [2]. High-dose curcumin supplements taken within 24-48 hours of an injection could theoretically worsen local bruising by reducing platelet aggregation.

Systemically, the FDA's boxed cardiovascular warning for romosozumab adds another layer. Curcumin has been studied for cardiovascular protection, with a 2017 meta-analysis (8 RCTs, N=577) reporting reductions in LDL cholesterol and triglycerides [11]. Whether this cardioprotective signal meaningfully interacts with Evenity's CV risk profile is purely speculative at present.

What Interaction Databases Rate This

The Natural Medicines Database rates high-dose curcumin as having a "minor" interaction with anticoagulant and antiplatelet drugs, citing the platelet aggregation data above. Romosozumab itself is not classified as an anticoagulant, so the direct drug-curcumin interaction is listed as theoretical rather than established. Mayo Clinic Proceedings guidance on supplement-drug interactions notes that anti-inflammatory botanicals warrant disclosure to prescribers managing bone-active therapies, though romosozumab is not singled out [12].

Dose-Dependent Risk: A Practical Framework

Not all turmeric is the same. The risk gradient runs from negligible at culinary intake to clinically discussable at high-extract doses.

Culinary Turmeric (Food Amounts)

A teaspoon of ground turmeric contains approximately 200 mg total curcuminoids, with poor absorption in the absence of fat or piperine [6]. Cooking turmeric into curries, soups, or golden milk at normal serving sizes delivers systemic curcumin concentrations too low to meaningfully affect platelet function. Patients using Evenity do not need to eliminate turmeric from their diet.

Low-Dose Supplements (200-500 mg curcuminoids/day)

Standardized extracts in this range are widely used for joint discomfort. Bioavailability-enhanced formulations at these doses may achieve plasma concentrations associated with modest COX-2 suppression [7]. The antiplatelet effect at this dose tier is likely subclinical in most patients, but disclosure to the prescriber is still appropriate given the injection-site bruising risk.

High-Dose Supplements (>500 mg curcuminoids/day, especially enhanced formulations)

Doses above 500 mg/day of bioavailability-enhanced curcumin reach plasma levels where antiplatelet activity has been measured in clinical studies [9]. Patients taking these doses in the 48 hours before or after a romosozumab injection should discuss timing or temporary dose reduction with their physician. No published guideline specifies an exact washout window, but curcumin's plasma half-life of approximately 6-7 hours [7] means that a 24-48 hour pause before injection would substantially reduce circulating levels.

Monitoring and What to Watch For

Patients on romosozumab who also use curcumin supplements should track a short list of signals.

Injection-Site Monitoring

Check the injection site 24-72 hours after each monthly administration. Mild redness and tenderness lasting under 72 hours are expected. A hematoma larger than 2 cm, significant swelling, or bruising that spreads beyond the immediate injection area should be reported to the prescribing clinician. Photograph the site if bruising appears, since the image provides a baseline for subsequent injections.

Systemic Bleeding Signs

High-dose curcumin rarely causes systemic bleeding in otherwise healthy adults without a coagulopathy. Still, patients on concurrent anticoagulants (warfarin, apixaban, rivaroxaban) or antiplatelets (aspirin, clopidogrel) face a compounding risk. A 2020 review in the British Journal of Clinical Pharmacology documented multiple case reports of curcumin potentiating warfarin anticoagulation, with INR elevations requiring dose adjustment [13]. If romosozumab is being taken alongside any anticoagulant, curcumin supplementation warrants explicit pharmacist review.

Bone Density Follow-Up

Romosozumab treatment is limited to 12 monthly injections, after which patients typically transition to antiresorptive therapy (bisphosphonates or denosumab) to preserve gains [3]. A dual-energy X-ray absorptiometry (DXA) scan at 12 months documents treatment response. No published data indicate that curcumin supplementation blunts the bone mineral density response to romosozumab, but patients who use high-dose curcumin throughout treatment and show unexpectedly modest DXA improvement might discuss this variable with their clinician.

What the Guidelines Say About Supplements During Bone Therapy

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines for osteoporosis management recommend disclosing all supplements to the treating clinician and note that anti-inflammatory botanicals may carry theoretical interactions with bone-active agents [14]. The Endocrine Society similarly advises that patients on anabolic bone therapies report supplement use at every visit [15].

Neither guideline specifically names curcumin as contraindicated with romosozumab. The absence of a contraindication listing reflects the absence of documented harm, not a confirmed safety signal.

Calcium and Vitamin D: The Supplements That Actually Matter With Evenity

The prescribing information for Evenity explicitly states that patients should receive adequate calcium and vitamin D during treatment [1]. Hypocalcemia can worsen with romosozumab use. The label recommends at least 1,000 mg elemental calcium and 800 IU vitamin D daily for patients with dietary insufficiency. These are the supplement interactions best documented for this drug, and they are positive (supportive) rather than adverse.

Talking to Your Prescriber: What to Say

Bring a written list of every supplement, its dose, and the formulation (standard vs. Enhanced bioavailability) to your Evenity appointment. A phrase that covers the key facts: "I take [X] mg of curcumin as [brand/formulation] daily. I wanted you to know before today's injection in case you want to adjust timing."

Your prescriber may ask you to hold the supplement for 48 hours before and after each injection as a practical precaution. This is a reasonable, low-burden approach given the pharmacokinetic half-life data and the lack of evidence of harm at culinary or low-supplement doses [7].

If you are also taking warfarin, a DOAC, or any antiplatelet agent, a pharmacist review of your full supplement list is warranted before continuing curcumin at any dose above 200 mg/day.

Special Populations

Patients With Prior Cardiovascular Events

Because romosozumab is contraindicated in patients with MI or stroke within the past 12 months [1], any patient who was recently cleared to start Evenity (meaning their CV event is more than one year old) is still in a higher-risk group. Curcumin's modest antiplatelet activity is an additional variable worth flagging with the cardiologist managing their secondary prevention regimen.

Patients With Inflammatory Conditions

Osteoporosis secondary to rheumatoid arthritis or inflammatory bowel disease often drives high-dose curcumin use in this population, since patients seek non-NSAID anti-inflammatory relief. These are also patients on corticosteroids, which independently accelerate bone loss. The clinical picture is complex. Curcumin's anti-inflammatory benefit is real [10], but coordination between the rheumatologist, gastroenterologist, and the clinician managing romosozumab is essential.

Postmenopausal Patients on Hormone Therapy

Some postmenopausal patients combine romosozumab with hormone therapy for concurrent symptom management. Curcumin has weak phytoestrogenic properties at very high doses in animal models [16], though this effect has not been demonstrated at human supplement doses. This remains a theoretical note rather than a clinical warning.